{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:48:50Z","timestamp":1772574530036,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.bbmt.2014.06.022","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T23:31:15Z","timestamp":1403220675000},"page":"1618-1625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation"],"prefix":"10.1016","volume":"20","author":[{"given":"Betul","family":"Oran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.06.022_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.56.082103.104704","article-title":"Myelodysplastic syndrome","volume":"56","author":"Hofmann","year":"2005","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bbmt.2014.06.022_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V69.1.92.92","article-title":"Treatment of preleukemic syndromes with marrow transplantation","volume":"69","author":"Appelbaum","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib3","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V99.6.1943","article-title":"Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program","volume":"99","author":"Castro-Malaspina","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib5","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib6","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2010.28.3978","article-title":"Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the\u00a0international prognostic scoring system","volume":"29","author":"Schanz","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.022_bib7","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.022_bib8","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/leu.2010.258","article-title":"Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype","volume":"25","author":"Patnaik","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.06.022_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ajh.22034","article-title":"Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients","volume":"86","author":"Belli","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2014.06.022_bib14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2012-04-423046","article-title":"Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS","volume":"120","author":"Deeg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib15","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R)","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib16","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2012.41.6073","article-title":"Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome","volume":"31","author":"Valcarcel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.022_bib17","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib18","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.022_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.beha.2012.10.012","article-title":"Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?","volume":"25","author":"Horowitz","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2014.06.022_bib20","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","article-title":"Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies","volume":"30","author":"Damaj","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.022_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","article-title":"5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation","volume":"45","author":"Field","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/bmt.2011.86","article-title":"Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome","volume":"47","author":"Kim","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/bmt.2008.400","article-title":"Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome","volume":"43","author":"De Padua Silva","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib24","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3324\/haematol.2009.019182","article-title":"Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial","volume":"95","author":"de Witte","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.06.022_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbmt.2004.10.001","article-title":"Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome","volume":"11","author":"Scott","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2012.01.009","article-title":"Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS","volume":"18","author":"Gerds","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine\u00a0+\/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"17","author":"Andersson","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.022_bib28","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:42Z","timestamp":1761058122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114003723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1083879114003723"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.022","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}